Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Authors:
- 1 May 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (18) , 2895-2897
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case ReportDrugs in R&D, 2014
- Genetic Risk Factors for Pancreatic DisordersGastroenterology, 2013
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell LymphomaClinical Cancer Research, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2012
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment IIHistopathology, 2006